OTC · PKANF
Simply Better Brands Corp.
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
Loading market information…
OTC · MGCLF · USD
Stock price
Quote as of May 10, 2024, 01:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 94.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia. Beyond its core pipeline, MGC Pharmaceuticals also offers its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods. The company further extends its services to include consulting, particularly in clinical research. Established in 2014 and headquartered in West Perth, Australia, the company previously operated as Erin Resources Limited before rebranding to MGC Pharmaceuticals Limited in December 2015.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$0.22-$0.00 (-0.19%)
Antibe Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.19% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
$0.98$0.00 (0.0%)
Nuvo Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.64% below the high.
$0.08$0.00 (0.0%)
RIV Capital Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.66% below the high.
CA$0.02CA$0.00 (0.0%)
Red White & Bloom Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
£0.00-£0.00 (-2.33%)
Verici Dx plc’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
